Screener
Iovance Biotherapeutics, Inc. IOVA Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Short-term investments | 186,906 | 133,902 |
| Inventory | 55,590 | 51,678 |
| Prepaid expenses and other assets | 8,874 | 11,583 |
| Total Current Assets | 464,257 | 442,689 |
| Property and equipment, net | 131,464 | 131,112 |
| Intangible assets, net | 263,894 | 279,324 |
| Operating lease right-of-use assets | 43,480 | 45,899 |
| Restricted cash | 6,005 | 5,980 |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s total current assets?
- Iovance Biotherapeutics, Inc. (IOVA) reported total current assets of $464.26M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s total current assets changed year-over-year?
- Iovance Biotherapeutics, Inc.'s total current assets increased by 9.9% year-over-year, from $422.5M to $464.26M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s total current assets?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s total current assets has grown at a -7.0% compound annual growth rate (CAGR), from $636.1M to $442.69M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Iovance Biotherapeutics, Inc.'s total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude